Vertex Pharmaceuticals (VRTX) Q2 2026: Revenue Growth and Guidance Raise — Positive Outlook

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported its second quarter 2026 financial results, showcasing a notable performance with total revenue of $3.33 billion, reflecting a 12% increase compared to the second quarter of 2025. This growth is primarily attributed to the strong demand for cystic fibrosis (CF) therapies and the expansion into additional disease areas.

Key Financial Metrics

• Total Revenue: $3.33 billion, up $389 million or 12% YoY from $2.94 billion in Q2 2025.
• U.S. Revenue: $2.06 billion, an 11% increase from the previous year.
• International Revenue: $1.28 billion, a 14% increase from the previous year.
• GAAP Net Income: $1.1 billion, compared to $1.0 billion in Q2 2025.
• Non-GAAP Net Income: $1.2 billion, unchanged from the previous year.
• Basic EPS: $4.34, up from $4.02 in Q2 2025.
• Cash, Cash Equivalents, and Marketable Securities: $13.6 billion, up from $12.3 billion at the end of 2025.

Analyst View

This quarter's results are a positive development for shareholders, driven by robust revenue growth and a strong pipeline of products. The increase in revenue, particularly from CF therapies and new product launches like CASGEVY and JOURNAVX, indicates effective market penetration and demand. The company also raised its full-year revenue guidance to $13.1 billion to $13.2 billion, up from the previous range of $12.95 billion to $13.1 billion, which further underscores confidence in continued growth.

Operational Highlights

• Vertex's cystic fibrosis therapies continue to perform well, with $3.21 billion in CF product revenue, driven by new initiations of ALYFTREK and contributions from CASGEVY and JOURNAVX.
• CASGEVY generated $76 million in revenue, marking a 151% increase year-over-year.
• JOURNAVX revenue reached $50 million, representing a 71% quarter-over-quarter growth and more than quadrupling compared to $12 million in Q2 2025.
• The company is advancing its research pipeline, with a PDUFA date for povetacicept set for November 30, 2026.

Shareholder Returns and Future Guidance

Vertex continues to invest in its growth, with combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses projected to be between $6.3 billion to $6.45 billion for the year. The company also announced a pending acquisition of Crinetics Pharmaceuticals for $85.00 per share, totaling approximately $10.0 billion, which is expected to close in Q3 2026.

Forward Catalysts

Investors should closely monitor the upcoming PDUFA date for povetacicept and the completion of the Crinetics acquisition. Additionally, continued growth in CF therapies and the performance of new products like CASGEVY and JOURNAVX will be critical indicators of Vertex's trajectory in the coming quarters. The company’s ability to maintain its revenue growth and manage expenses effectively will be essential for sustaining shareholder value.

Note: The following tables represent amounts in millions.

Vertex Pharmaceuticals Incorporated

Consolidated Statements of Income

(unaudited, in millions, except per share amounts)

	Three Months Ended		Six Months Ended
	June 30, 2026	2025	June 30, 2026	2025
Product	$3,333.0	$2,944.0	$6,320.8	$5,704.0
net
Other	—	20.7	—	30.7
revenue
Total	$3,333.0	$2,964.7	$6,320.8	$5,734.9
revenue
Costs and
expenses
Cost of	$489.2	$407.5	$882.0	$770.5
sales
Research and	$993.8	$978.4	$1,955.4	$1,958.1
development
expenses
Acquired IPR&D	$21.4	$2.2	$21.9	$22.0
and
development
expenses
Selling,	$582.2	$424.6	$1,075.9	$821.0
general and
administrative
expenses
Intangible	—	—	—	$379.0
asset
impairment
charge
Change in	$0.4	$0.9	$0.6	$3.1
fair value
of
contingent
consideration
Total costs	$2,087.00	$1,813.6	$3,935.8	$3,953.0
and expenses
Income from	$1,246.00	$1,151.1	$2,385.0	$1,781.0
operations
Interest income	$120.60	$118.7	$235.4	$236.6
net
Other income	$24.3	$13.2	$24.3	-$4.4
(expense) net
Income before	$1,391.0	$1,283.0	$2,644.7	$2,013.0
provision for
income taxes
Provision for	$292.0	$250.1	$513.5	$334.2
income taxes
Net income	$1,099.0	$1,032.9	$2,131.2	$1,679.0
Net income
per common	$4.34	$4.02	$8.39	$6.54
share (Basic)
Diluted	$4.31	$3.99	$8.33	$6.48
Shares used in
per share
calculation
Basic	253.7	256.7	253.9	256.8
Diluted	255.2	258.9	255.7	259.2

Vertex Pharmaceuticals Incorporated

Condensed Consolidated Balance Sheets

(unaudited, in millions)

	June 30, 2026	December 31, 2025
Assets
Cash, cash equivalents and	$7,852.4	$6,608.1
marketable securities
Accounts receivable, net	2,134.3	2,052.8
Inventories	1,765.1	1,686.8
Prepaid expenses and other	791.9	853.3
current assets
Total current assets	12,543.7	11,201.0
Property and equipment, net	1,665.0	1,520.3
Goodwill and other intangible
assets, net	1,500.8	1,512.2
Deferred tax assets	3,010.9	2,897.9
Operating lease assets	1,662.9	1,562.7
Long-term marketable securities	5,789.1	5,712.3
Other long-term assets	1,250.9	1,236.6
Total assets	$27,423.3	$25,643.0
Liabilities and Shareholders'
Equity
Accounts payable and accrued	$3,608.5	$3,432.9
expenses
Other current liabilities	329.4	428.3
Total current liabilities	3,937.9	3,861.2
Long-term operating lease	1,977.6	1,846.5
liabilities
Other long-term liabilities	1,259.9	1,269.5
Shareholders' equity	20,247.9	18,665.8
Total liabilities and
shareholders' equity	$27,423.3	$25,643.0
Common shares outstanding	253.3	254.0

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.